2023 World Conference on Lung Cancer (Posters)-P1.22. A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC

P1.22. A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC - PDF(Slides)

Back to course

Pdf Summary

In this study, researchers evaluated the feasibility of a new next generation sequencing (NGS) panel test called the lung cancer compact panel (LCCP) for diagnosing non-small cell lung cancer using cytological specimens. The LCCP test allows for the use of cytological samples, which are easier and safer to collect than tissue biopsy samples. The study aimed to validate the usefulness of the LCCP test using cytology samples in a multicenter phase 3 trial.<br /><br />The study enrolled patients who underwent diagnostic procedures for lung cancer from March 2022 to March 2023. Cytology samples were collected using various methods such as bronchoscopy and needle puncture, and were stored in containers with nucleic acid protection agents. The primary endpoint of the study was the analysis success rate, defined as a nucleic acid yield of 10 ng or more for DNA/RNA and successful analysis of all 8 genes included in the LCCP panel.<br /><br />A total of 248 patients were included in the study, with an average age of 70.3 years and 63.7% of them being male. The clinical stages of the patients varied, with the majority being stage 4 (53.2%). The primary endpoint analysis showed that the LCCP gene analysis success rate using cytology samples was 98.4%, indicating high success in genetic mutation analysis. Among the 150 cases of lung adenocarcinoma with successful genetic analysis, 62% had gene mutations detected by the LCCP test.<br /><br />The study concluded that the LCCP test had a high success rate for genetic mutation analysis of cytology samples and showed superiority over conventional panel testing. The detection rate of gene mutations was also high. The researchers suggest that as lung cancer gene panels become simpler to use and less invasive, they may become more popular in clinical practice.<br /><br />Overall, this study demonstrates the feasibility and effectiveness of using the LCCP NGS panel test with cytological specimens for diagnosing non-small cell lung cancer.

Asset Subtitle

Kei Morikawa

Meta Tag

Speaker Kei Morikawa

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

next generation sequencing

NGS panel test

lung cancer compact panel

LCCP

non-small cell lung cancer

cytological specimens

diagnosis

bronchoscopy

needle puncture

genetic mutation analysis